Expect the GLP-1 era to stick around, she said
But by and large, for the vast majority of people, they are relatively safe, and side effects that they experience on the medication should go away if they were to stop
30 30 5.00 5 200 20 5.00 5 10 60 10 60 30 4.67 5 32 4.67 5 3 15 10 60 5 60 4.33 5
Nat Commun 15 , 1042 (2024)
Danaei M, Dehghankhold M, Ataei S, HasanzadehDavarani F, Javanmard R, Dokhani A, et al
The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration